LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Cerrado

SectorSanidad

59.52 -0.1

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

59.51

Máximo

59.68

Métricas clave
By Trading Economics
Ingresos	1.6B 2.7B
Ventas	-1B 11B
P/B Media del Sector	15.964 49.701
BPA	1.58
Rentabilidad por dividendo	4.39
Margen de beneficios	23.309
Empleados	32,500
EBITDA	1.5B 3.7B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+8.12% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	4.39% 2.39%
Próximas Ganancias	30 jul 2026
Fecha Próximo Dividendo	31 jul 2026
Próxima Fecha de Ex Dividendo	2 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-940M 117B
Apertura anterior	59.62
Cierre anterior	59.52

Noticias sobre sentimiento de mercado

By Acuity

33%

67%

76 / 345 Clasificación en Healthcare

Bristol-Myers Squibb Co. Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2026, 06:42 UTC

Principales Movimientos del Mercado

Bristol Myers Squibb and China's Hengrui Pharma Forge Tie-Up

30 abr 2026, 11:14 UTC

Ganancias

Bristol Myers Squibb Logs Higher 1Q Sales Driven by Growth Portfolio

5 may 2026, 18:12 UTC

Ganancias

BioNTech to Slash 22% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

5 may 2026, 13:54 UTC

Ganancias

BioNTech to Slash 25% of Workforce as Losses Widen. The Stock Falls. -- Barrons.com

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: Continue to See Total Worldwide Eliquis Revenue Increasing 10%-15% in 2026 Vs Yr-Ago >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: 2026 Guidance Excludes Impact of Any Potential Future Strategic Acquisitions, Divestitures and Impact of Future Acquired IPRD Charges and Licensing Income >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: Reaffirming 2026 Financial Guidance With Total Revenue and Diluted EPS Trending Toward Upper End of Ranges >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb Backs 2026 Rev $46B-$47.5B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q International Revenue Rose 11% to $3.7B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: 1Q Results Reflecting Sustained Momentum Across Our Growth Portfolio and Disciplined Execution Throughout the Business >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q U.S. Revenue Fell 1% to $7.79B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Rev $11.49B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: In Legacy Portfolio, Demand Increased for Eliquis in 1Q, Which Was More Than Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: 1Q Growth Portfolio Revenue Increase Primarily Driven by Reblozyl, Camzyos and Breyanzi >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Eliquis Revenue Rose 16% to $4.14B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb Backs 2026 Adj EPS $6.05-Adj EPS $6.35 >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Adjusted Gross Margin 70.3% >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 12% to $6.23B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q EPS $1.31 >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 6% to $5.28B >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Adj EPS $1.58 >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb: Latest 1Q Includes Net Impact of Loss of 3c/Shr Due to Acquired IPRD Charges and Licensing Income >BMY

30 abr 2026, 10:59 UTC

Ganancias

Bristol Myers Squibb 1Q Gross Margin 70.2% >BMY

14 abr 2026, 14:13 UTC

Ganancias

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 abr 2026, 12:57 UTC

Ganancias

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14 abr 2026, 11:19 UTC

Ganancias

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

14 abr 2026, 10:34 UTC

Ganancias

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

13 abr 2026, 21:23 UTC

Ganancias

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

6 feb 2026, 12:35 UTC

Ganancias

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

5 feb 2026, 15:25 UTC

Ganancias

Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. -- Barrons.com

Comparación entre iguales

Cambio de precio

Bristol-Myers Squibb Co. previsión

Precio Objetivo

By TipRanks

8.12% repunte

Estimación a 12 Meses

Media 64.29 USD 8.12%

Máximo 75 USD

Mínimo 54 USD

De acuerdo con 18 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

18 ratings

Comprar

Mantener

Vender

De acuerdo con 18 analistas que ofrecen calificaciones bursátiles a para Bristol-Myers Squibb Co. Dist en los últimos 3 meses.

Sentimiento

By Acuity

76 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.